An interventional study of Educational Intervention and Electronic Health Record Review in Breast Carcinoma, Colorectal Carcinoma and Lung Carcinoma, sponsored by University of Michigan Rogel Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University of Michigan Rogel Cancer Center · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · University of Michigan Rogel Cancer Center.
Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, this one is the 9th largest by planned enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, and was the 47th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →5 of the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center are open now, in 1 country. Recruiting first, the newest first:
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Women only
University of Michigan Rogel Cancer Center · Sites in United States
Ages 60–85 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 12 · Phase 4 1
First in 1999; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 71 is close to the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 34 across the 36 interventional studies, 68 across the 11 observational. Of the 40 that completed or were terminated, 14 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan Rogel Cancer Center is the lead sponsor of 325 studies on the registry; 49 are open to participants now.
Of its 46 completed or terminated interventional studies of FDA-regulated products, 31 (67%) have results posted.
5 of the studies in Breast Neoplasms by University of Michigan Rogel Cancer Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183126University of Michigan Rogel Cancer CenterPharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer | 2026-11 |
| NCT06100263University of Michigan Rogel Cancer CenterBreast Cancer Resiliency Through Exercise Program (B-REP) | 2026-12 |
| NCT05996107University of Michigan Rogel Cancer CenterStudy of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer | 2027-02 |
| NCT06915168University of Michigan Rogel Cancer CenterCIPN Decision Aid for the Improvement of Chemotherapy Decision Making in Patients With Breast Cancer | 2027-03 |
| NCT07291414University of Michigan Rogel Cancer CenterA Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients | 2027-03-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 48 studies in Breast Neoplasms by University of Michigan Rogel Cancer Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients use the self-monitoring platform to track medication-related safety events and issues at home for 6 months. Patients may receive relevant educational materials and resources via the platform or by email and/or receive follow-up contact from a nurse practitioner as needed over the 6 months. Patients are encouraged to continue using the platform for an additional 6 months after the study period, as desired.
Other: Educational Intervention · Other: Electronic Health Record Review · Procedure: Follow-Up · Other: Internet-Based Intervention · Other: Interview · Other: Survey Administration
Receive educational materials and resources
Also known as: Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational
Ancillary studies
Receive follow-up contact
Also known as: Active Follow-up, Clinical Signs Follow-up, CLSFUP, Follow Up, follow_up, Followed, Followup
Use self-monitoring platform
Ancillary studies
Ancillary studies
Self-reported system usability
Self-reported system usability will be assessed using the 10-item System Usability Scale. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 6 months
Perceived usefulness
Qualitative data, including brief interview data will be analyzed and summarized through content analysis.
Time frame: Up to 6 months
Ease of use
Qualitative data, including brief interview data will be analyzed and summarized through content analysis.
Time frame: Up to 6 months
Attitudes toward use
Qualitative data, including brief interview data will be analyzed and summarized through content analysis.
Time frame: Up to 6 months
Intention to use and continuous use of the system over time
Qualitative data, including brief interview data will be analyzed and summarized through content analysis.
Time frame: Up to 12 months
Self-reported patient engagement
Self-reported patient engagement will be measured by the 9-item Twente Engagement with Ehealth Technologies Scale (TWEETS), including three dimensions, behavioral engagement, cognitive engagement, and affective engagement. Will use the overall TWEETS score to evaluate patient engagement in this study, rather than analyzing each dimension separately. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables. Will use repeated measures analysis of variance to assess the changes in mean scores of patient engagement. Univariate associations between baseline personal and clinical factors and patient engagement at each time point will be assessed using correlation analyses (Pearson or Spearman), Chi-square tests, or non-parametric Mann-Whitney U tests, depending on the variable types. Multiple linear regressions will be conducted to assess associations between patient engagement and outcomes.
Time frame: Up to 6 months
System usage over time
Will be objectively recorded by the system logs and analyzed using Google Analytics (dashboard only), including parameters like the number of logins, number of tab pages clicked, number of events or concerns self-tracked, and more. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 12 months
Patient activation levels
Patient activation levels will be measured by the Short Form of Patient Activation Measure. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 6 months
Medication self-management ability
Medication self-management ability will be measured by the Measure of Medication Self-Management. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 6 months
Symptom distress
Symptom distress will be measured by the 19-item MD Anderson Symptom Inventory. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 6 months
Health related quality of life
Health-related quality of life will be measured by the 27-item Functional Assessment of Cancer Therapy - General. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 6 months
Number of emergency room visits
Will be measured by both self-report and chart review. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 12 months
Number of hospitalizations
Will be measured by both self-report and chart review. Will use descriptive statistics, such as mean and standard deviation for continuous variables, and frequency and percentage for categorical variables.
Time frame: Up to 12 months
User experiences with the system
Participants' user experiences with the system, such as perceived facilitators or barrios to system use, along with their suggestions for system improvement, will be collected through a brief individual interview. Qualitative data, including brief interview data will be analyzed and summarized through content analysis.
Time frame: Up to 6 months
Self-tracked, structured medication safety events or concerns
To understand the nature and causes of events and concerns, self-tracked, structured medication safety events or concerns tracking data from the system, such as the number and types of events or concerns self-tracked, will be summarized using descriptive statistics. The free-text tracking data from the system will be analyzed and summarized through content analysis or natural language processing techniques, depending on data volume.
Time frame: Up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 13 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jan 2028 → Mar 2027 and completion Jan 2028 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Michigan Rogel Cancer Center →